204 related articles for article (PubMed ID: 36198883)
1. Neuropathology of central nervous system involvement in TTR amyloidosis.
Taipa R; Sousa L; Pinto M; Reis I; Rodrigues A; Oliveira P; Melo-Pires M; Coelho T
Acta Neuropathol; 2023 Jan; 145(1):113-126. PubMed ID: 36198883
[TBL] [Abstract][Full Text] [Related]
2. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
3. CNS Involvement in Hereditary Transthyretin Amyloidosis.
Sousa L; Coelho T; Taipa R
Neurology; 2021 Dec; 97(24):1111-1119. PubMed ID: 34663645
[TBL] [Abstract][Full Text] [Related]
4. [Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis].
Ikeda SI
Brain Nerve; 2013 Jul; 65(7):831-42. PubMed ID: 23832986
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
Gonçalves P; Martins H; Costelha S; Maia LF; Saraiva MJ
Amyloid; 2016 Dec; 23(4):249-253. PubMed ID: 27884058
[TBL] [Abstract][Full Text] [Related]
6. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
[TBL] [Abstract][Full Text] [Related]
7. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
Adams D; Koike H; Slama M; Coelho T
Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302
[TBL] [Abstract][Full Text] [Related]
8. Hereditary transthyretin amyloidosis overview.
Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
[TBL] [Abstract][Full Text] [Related]
9. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
11. Oculoleptomeningeal Amyloidosis Secondary to the Rare Transthyretin c.381T>G (p.Ile127Met) Mutation.
Mathieu F; Morgan E; So J; Munoz DG; Mason W; Kongkham P
World Neurosurg; 2018 Mar; 111():190-193. PubMed ID: 29277593
[TBL] [Abstract][Full Text] [Related]
12. The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis.
Moreira J; Costelha S; Saraiva M; Saraiva MJ
Front Immunol; 2021; 12():650269. PubMed ID: 34093538
[TBL] [Abstract][Full Text] [Related]
13. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin Variant Amyloidosis with a TTR A97D (p.A117D) Mutation Manifesting Remarkable Asymmetric Neuropathy.
Ikeda K; Yamamoto D; Usui K; Takeuchi H; Oka N; Katoh N; Yazaki M; Kametani F; Nishino I; Hisahara S
Intern Med; 2023 Aug; 62(15):2261-2266. PubMed ID: 36543209
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin amyloidosis: a new mutation associated with dementia.
Petersen RB; Goren H; Cohen M; Richardson SL; Tresser N; Lynn A; Gali M; Estes M; Gambetti P
Ann Neurol; 1997 Mar; 41(3):307-13. PubMed ID: 9066351
[TBL] [Abstract][Full Text] [Related]
16. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
17. Rare c.302C>T
Žebrauskienė D; Sadauskienė E; Masiulienė R; Aidietienė S; Šiaudinienė A; Pečeliūnas V; Žukauskaitė G; Žurauskas E; Valevičienė N; Barysienė J; Preikšaitienė E
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399526
[No Abstract] [Full Text] [Related]
18. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E; Kyriakides T
Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
[TBL] [Abstract][Full Text] [Related]
19. TLR2 and 4 signaling pathways are altered in macrophages from V30M TTR mice with down-regulated expression of chemokines.
Moreira J; Martins H; Saraiva M; Saraiva MJ
Clin Sci (Lond); 2023 Mar; 137(5):355-366. PubMed ID: 36852978
[TBL] [Abstract][Full Text] [Related]
20. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]